Cytovance Biologics hires vp of sales and business development

Valerie McDonnell joins from Althea

Cytovance Biologics, a biopharmaceutical contract manufacturing company specialising in the production of therapeutic proteins and antibodies from mammalian cell culture, has appointed Valerie McDonnell as vice president of sales and business development.

McDonnell has more than 22 years’ experience in the biotech industry. Prior to joining Cytovance she was vice president of sales at Althea.

Before joining Althea she was a study director at BioReliance where she was responsible for client programmes in the Molecular Biology Department. She also worked at The Institute for Genomic Research (TIGR) and participated in the Haemophilus influenzae sequencing programme.

You may also like

Manufacturing

Avantor and Cytovance collaborate on plasmid DNA supply

The collaboration extends Avantor’s offering of critical materials for vaccines and therapeutics focused on cell and gene therapy
Manufacturing

Cytovance Biologics to expand microbial manufacturing

Has acquired 100L and 1,000L fermenters
Manufacturing

Cytovance Biologics to expand production capabilities in 2013

Installs a 1,000L SUB bioreactor, 5,000L stainless steel bioreactor and fill/finish line
Manufacturing

Cytovance adds 1,000L bioreactor to mammalian facility

Will complement existing manufacturing process trains in Oklahoma City
You need to be a subscriber to read this article.
Click here to find out more.
Personal Protection

Gas safety in smaller pharmaceutical facilities

Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees
Analysis

Efficient extraction of proteins from bacterial cells

SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells
Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Subscribe now